Pharmaceuticals Acquisitions in Massachusetts
Massachusetts Pharma Deal Patterns
Across recent pharmaceuticals acquisitions in Massachusetts, United States, buyers are pursuing a mix of late-stage pipeline expansion, commercial product lift, and targeted platform capabilities. Deals span large multinational strategic transactions as well as portfolio-building moves by life sciences focused investors.
Several transactions emphasize building or reshaping therapeutic focus—such as rare immunology and neuroscience—while others focus on strengthening U.S. commercial presence or accelerating development through specialized drug-delivery and delivery technology collaborations. Common deal mechanics include tender offers, all-cash acquisitions, and structures that incorporate contingent value rights (CVRs).
The activity also shows how Massachusetts can serve as a home base for specialty biopharma targets and enabling technology companies, with acquirers aligning to assets such as oncology and bone health programs, gastroenterology products, and lipid nanoparticle (LNP)–related capabilities.
What Stands Out
- Sanofi agreed to acquire Blueprint Medicines to expand a rare immunology pipeline (including BLU-808 with milestone payments via a contingent value right).
- Novartis moved to bolster its pipeline by acquiring Anthos Therapeutics (announced via a transaction “up to $3.1B,” including an upfront payment).
- Commercial and product-focused strategy appears in Azurity Pharmaceuticals’ acquisition of Sebela Pharmaceuticals’ bowel prep franchise and in Bristol Myers Squibb’s acquisition of Karuna Therapeutics.
- Delivery and enabling-technology investment surfaces through NOF CORPORATION’s strategic minority investment in Hopkinton-based Phosphorex to accelerate cGMP capabilities and LNP collaboration.
- Deal structures frequently use tender offers and may include CVRs—seen in transactions such as Paratek Pharmaceuticals (NUZYRA–linked CVR) and Assertio Holdings (CVR tied to ROLVEDON commercialization).
-
January 12, 2026
- Buyer
- B-FLEXION Life Sciences
- Target
- Radius Health
- Seller
- Affiliates of Patient Square Capital, Webster Equity Partners
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
B-FLEXION Life Sciences has agreed to purchase the remaining 57% interest in Radius Health held by affiliates of Patient Square Capital and Webster Equity Partners. Radius, a specialty biopharmaceutical focused on bone health, had been taken private by B-FLEXION and Patient Square in August 2022. The transaction is expected to close by the end of Q1 2026.
-
November 17, 2025
- Buyer
- Azurity Pharmaceuticals
- Target
- Sebela Pharmaceuticals' Bowel Prep Franchise
- Seller
- Sebela Pharmaceuticals
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Divestiture
Azurity Pharmaceuticals has acquired Sebela Pharmaceuticals' bowel preparation franchise, including two leading bowel prep therapies used for colonoscopies. The deal transfers Sebela's commercial team (more than 50 colleagues) and is intended to strengthen Azurity's gastroenterology product portfolio and U.S. market presence.
-
- Buyer
- Sanofi
- Target
- Blueprint Medicines Corporation
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Sanofi and Blueprint Medicines entered into an agreement under which Sanofi will acquire Blueprint via a cash tender offer and subsequent merger. The deal values Blueprint at $129.00 per share in cash (approximately $9.1 billion equity value), with additional potential milestone payments tied to BLU-808 via a contingent value right.
-
February 11, 2025
- Buyer
- Novartis
- Target
- Anthos Therapeutics, Inc., Anthos Therapeutics
- Seller
- Anthos Therapeutics shareholders
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Blackstone Life Sciences and Anthos Therapeutics announced that Novartis will acquire Anthos for up to $3.1 billion, including a $925 million upfront payment to Anthos shareholders. The deal is expected to close in the first half of 2025, subject to customary closing conditions and regulatory approvals. Novartis later completed the acquisition, valuing the transaction at up to $3.1 billion with the $925 million upfront payment.
-
- Buyer
- NOF CORPORATION
- Target
- Phosphorex
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Growth capital
Japanese chemical manufacturer NOF Corporation completed a strategic minority investment in Phosphorex, a Hopkinton, Massachusetts-based drug-delivery CDMO backed by Ampersand Capital Partners. The investment will fund acceleration of Phosphorex's cGMP capabilities and strengthen collaboration on lipid nanoparticle (LNP) technologies and NOF's COATSOME SS series ionizable lipids.
-
June 12, 2024
- Buyer
- Ono Pharmaceutical Co., Ltd., Topaz Merger Sub Inc.
- Target
- Deciphera Pharmaceuticals Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Ono Pharmaceutical Co., Ltd. completed its previously announced tender offer to acquire all outstanding shares of Deciphera Pharmaceuticals Inc. for $25.60 per share, totaling approximately $2.4 billion. Following the tender offer, a wholly-owned subsidiary merged with and into Deciphera, with Deciphera surviving as a wholly owned subsidiary of Ono.
-
December 22, 2023
- Buyer
- Bristol Myers Squibb
- Target
- Karuna Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Bristol Myers Squibb (BMS) and Karuna Therapeutics entered into a definitive merger agreement under which BMS will acquire Karuna for $330 per share in cash, valuing Karuna’s equity at about $14.0 billion (about $12.7 billion net of estimated cash acquired). The deal is expected to close in the first half of 2024, subject to customary approvals and regulatory conditions.
-
December 6, 2023
- Buyer
- AbbVie Inc.
- Target
- Cerevel Therapeutics
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
AbbVie (AbbVie Inc.) announced it will acquire Cerevel Therapeutics in a definitive agreement, strengthening its neuroscience pipeline with multiple clinical- and preclinical-stage programs. The deal values Cerevel at about $8.7 billion and is structured as an all-cash purchase of all outstanding Cerevel shares for $45.00 per share.
-
November 20, 2023
- Buyer
- Zevra Therapeutics, Inc.
- Target
- Acer Therapeutics, Inc.
- Seller
- Acer Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Zevra Therapeutics completed the acquisition of Acer Therapeutics in a stock-and-contingent-value-rights transaction, bringing the FDA-approved product OLPRUVA and clinical-stage candidate EDSIVO into Zevra's portfolio and transitioning Zevra to a commercial-stage rare disease company. The deal included Zevra's purchase of Acer's senior secured debt and issuance of approximately 2.96 million shares plus CVRs (up to $76 million), and was followed by a registered direct offering to a healthcare-focused investment fund.
-
September 21, 2023
- Buyer
- Gurnet Point Capital, Novo Holdings A/S
- Target
- Paratek Pharmaceuticals, Inc.
- Seller
- Paratek Pharmaceuticals stockholders
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Gurnet Point Capital and Novo Holdings completed the acquisition of Paratek Pharmaceuticals for $2.15 per share in cash plus a $0.85 CVR tied to NUZYRA sales, in a transaction valued at approximately $462 million including assumed debt. Oaktree provided $175 million of debt financing; following closing Paratek will be taken private and delisted from Nasdaq as the buyers aim to accelerate commercialization of NUZYRA and expand Paratek's anti-infective portfolio.
-
August 1, 2023
- Buyer
- Revolution Medicines, Inc.
- Target
- EQRx, Inc.
- Seller
- EQRx stockholders
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Revolution Medicines (NASDAQ: RVMD) has agreed to acquire EQRx (NASDAQ: EQRX) in an all‑stock transaction that will transfer more than $1 billion in net cash to Revolution’s balance sheet. The deal is intended to strengthen Revolution Medicines’ financial position to accelerate clinical development of its RAS(ON) inhibitor pipeline while EQRx will wind down most of its R&D programs post-closing.
-
April 25, 2023
- Buyer
- Assertio Holdings, Inc.
- Target
- Spectrum Pharmaceuticals, Inc.
- Seller
- Spectrum stockholders
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Assertio Holdings, Inc. agreed to acquire all outstanding shares of Spectrum Pharmaceuticals, Inc. in an all-stock transaction with contingent value rights (CVRs), expected to close in Q3 2023. The deal combines Assertio's digital, non-personal commercial capabilities with Spectrum's in-person commercial team and ROLVEDON (eflapegrastim-xnst) to accelerate the product's launch and broaden the combined company's pharmaceutical portfolio.
-
- Buyer
- Takeda Pharmaceutical Company Limited
- Target
- Nimbus Lakshmi, Inc.
- Seller
- Nimbus Therapeutics, LLC
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Takeda Pharmaceutical Company Limited has completed the acquisition of all shares of Nimbus Lakshmi, Inc. (the TYK2 program subsidiary of Nimbus Therapeutics) for approximately $4.0 billion upfront, with up to $2.0 billion in potential milestone payments. The deal adds TAK-279 (NDI-034858), a selective oral TYK2 inhibitor moving into late‑stage development, strengthening Takeda's late‑stage pipeline in immune‑mediated diseases including psoriasis and other immunological indications.
-
January 20, 2023
- Buyer
- LG Chem, Ltd.
- Target
- AVEO Oncology
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
LG Chem completed its all-cash acquisition of AVEO Oncology for an implied equity value of $571 million, making AVEO a wholly owned subsidiary of LG Chem Life Sciences Innovation Center. The deal expands LG Chem’s oncology capabilities and commercial footprint in the United States while positioning AVEO to leverage LG Chem’s R&D and manufacturing resources to advance its oncology pipeline and commercialization efforts.
-
January 18, 2023
- Buyer
- Cambrex
- Target
- Snapdragon Chemistry
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Cambrex has acquired Snapdragon Chemistry, a Waltham, Massachusetts-based specialist in API batch and continuous flow process development. The deal brings Snapdragon's ~70–75 scientists and engineers (including 31 PhDs) and continuous flow capabilities into Cambrex's global CDMO platform to expand its process development and manufacturing offerings.
-
August 12, 2022
- Buyer
- Ipsen
- Target
- Epizyme, Inc. (Epizyme)
- Seller
- Royalty Pharma (support agreement; agreed to tender shares)
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Ipsen completed its acquisition of Epizyme under a definitive merger agreement, acquiring all outstanding shares for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. The deal expands Ipsen’s oncology portfolio with Epizyme’s lead medicine Tazverik (tazemetostat) and development candidate EZM0414, among other preclinical programs.
-
July 11, 2022
- Buyer
- Innoviva, Inc., Innoviva (wholly owned subsidiary)
- Target
- La Jolla Pharmaceutical Company
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Innoviva entered into a definitive merger agreement to acquire La Jolla Pharmaceutical Company for $6.23 per share in cash (including a tender offer), representing an implied enterprise value of about $149 million. The acquisition adds GIAPREZA and XERAVA to Innoviva’s infectious disease and hospital portfolio and was completed in August 2022, with La Jolla becoming a wholly owned subsidiary and delisted from Nasdaq.
-
- Buyer
- Alcon Inc.
- Target
- Kala Pharmaceuticals, Inc.
- Seller
- Kala Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Divestiture
Alcon Inc. agreed to acquire the commercial portfolio and related intellectual property for EYSUVIS and INVELTYS from Kala Pharmaceuticals for an upfront payment of $60 million, with Kala eligible for future commercial milestone payments. The asset sale allows Alcon to expand its ophthalmic drug franchises while enabling Kala to focus on its pipeline (KPI-012) and extend its cash runway.
-
- Buyer
- Taiho Pharmaceutical Co., Ltd.
- Target
- Cullinan Pearl Corp.
- Seller
- Cullinan Oncology, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Divestiture
Taiho Pharmaceutical Co., Ltd. will acquire Cullinan Pearl Corp., a subsidiary of Cullinan Oncology, for $275 million upfront plus up to $130 million in regulatory milestone payments, and will co-develop and co-commercialize CLN-081/TAS6417. Cullinan Oncology will retain co-development and an option to co-commercialize in the U.S.; the deal provides Cullinan Oncology with cash to extend its runway and reduces its development and pre-commercialization costs.
-
November 11, 2021
- Buyer
- Pharmacosmos A/S
- Target
- AbFero Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Pharmacosmos A/S (Pharmacosmos Group) has agreed to acquire all assets of Boston-based clinical-stage AbFero Pharmaceuticals, Inc. under a share purchase agreement for up to $225 million including upfront, milestone, and royalty components. The acquisition adds AbFero’s SP-420 iron chelation program to Pharmacosmos’ iron-metabolism-focused R&D and commercial capabilities to accelerate development and commercialization for transfusional iron overload and related indications.
-
October 11, 2021
- Buyer
- Pacira BioSciences, Inc.
- Target
- Flexion Therapeutics, Inc.
- Seller
- Flexion Therapeutics stockholders, Flexion directors and executive officers (and affiliates)
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Pacira BioSciences agreed to acquire Flexion Therapeutics for $8.50 per share in cash plus one contingent value right (CVR) worth up to $8.00 per share tied to sales and regulatory milestones. The deal adds Flexion's marketed non-opioid OA knee pain therapy ZILRETTA and its clinical-stage pipeline to Pacira's non-opioid pain management portfolio; the transaction was expected to close in Q4 2021 and to be accretive to Pacira's earnings.
-
November 16, 2020
- Buyer
- Covis Group S.à r.l.
- Target
- AMAG Pharmaceuticals, Inc.
- Seller
- Public shareholders of AMAG Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Covis Group S.à r.l. completed a cash tender offer and merger to acquire AMAG Pharmaceuticals, Inc. for $13.75 per share, taking AMAG private and delisting its NASDAQ shares. The acquisition adds AMAG’s marketed products (including Feraheme and Makena) and development-stage assets in women’s health and hematology/oncology to Covis’ specialty pharma portfolio, supported by financing from Capital One and investment funds managed by HPS Investment Partners.
-
June 28, 2018
- Buyer
- Novacap
- Target
- PCI Synthesis
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Novacap has completed the acquisition of PCI Synthesis, a U.S.-based small-molecule CDMO with R&D and manufacturing sites in Massachusetts. The deal gives Novacap a U.S. footprint and strengthens its global pharmaceutical synthesis and commercial manufacturing capabilities.
-
July 2, 2014
- Buyer
- Nicox S.A.
- Target
- Aciex Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
Nicox S.A. agreed to acquire Aciex Therapeutics, Inc., a U.S.-based ophthalmic development company, in a share-exchange deal that will transfer 100% of Aciex to Nicox. The transaction (approved by Nicox shareholders on October 22, 2014) issues 20,627,024 new Nicox shares for Aciex equity and includes contingent value rights giving up to $55 million in potential additional consideration tied to FDA approvals, and is intended to broaden Nicox's ophthalmic development pipeline.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.
Frequently Asked Questions
What kinds of acquisitions are driving Massachusetts pharmaceuticals activity?
Transactions include strategic pipeline expansions, commercial product/franchise purchases, and investments that support enabling capabilities such as drug-delivery CDMO work and lipid nanoparticle (LNP) technology.
Do these deals use common acquisition structures like tender offers and CVRs?
Yes. Multiple transactions are structured as tender offers or acquisitions followed by mergers, and some include contingent value rights (CVRs) tied to product sales or milestones.
Which acquirers show up repeatedly in this Massachusetts set?
Recurring names include Ipsen, Revolution Medicines, Inc., Taiho Pharmaceutical Co., Ltd., B-FLEXION Life Sciences, Innoviva, Inc., Bristol Myers Squibb, and Novartis.
Are the targets based in Massachusetts?
The deals listed are located in Massachusetts, United States, and targets include Massachusetts-based companies such as Phosphorex (Hopkinton) and other pharmaceutical and biopharma businesses with Massachusetts ties.